Biocon reported double-digit year-over-year growth in its Biosimilars and Generics businesses for Q2 FY26. The company strengthened its balance sheet by settling debt obligations, and successfully launched bUstekinumab, bAspart, bBevacizumab, and bAflibercept. A key milestone was achieved with US FDA approval for bDenosumab. Q2 FY26 revenue from operations stood at ₹4,296 Cr with Core EBITDA at ₹1,218 Cr.
Financial Performance
Q2 FY26 saw strong performance across key business segments:
- Revenue from Operations: ₹4,296 Cr, a 20% increase year-over-year.
- Core EBITDA: ₹1,218 Cr, up 23% year-over-year.
- R&D (Net): ₹251 Cr
- Net Profit (Reported): ₹85 Cr
Biosimilars Business Update
The Biosimilars business demonstrated robust growth. Key highlights include:
- Segment Revenue: ₹2,721 Cr, a 25% increase year-over-year.
- Core EBITDA: ₹880 Cr
- Strong commercial traction for Yesintek.
- Continued performance in the oncology portfolio.
- Launch of bUstekinumab across seven markets in Europe.
Generics Business Update
The Generics segment also reported positive results:
- Segment Revenue: ₹774 Cr, a 24% increase year-over-year.
- Core EBITDA: ₹96 Cr
- Growth supported by recent product launches in the US and EU.
- Commenced global filings for semaglutide.
CRDMO Business Update (Syngene)
Syngene’s performance was steady, with the following highlights:
- Segment Revenue: ₹911 Cr, a 2% increase year-over-year.
- Reported EBITDA: ₹215 Cr
- Secured its first global phase III clinical trial from a U.S.-based biotech company.
Strategic Initiatives
Biocon is focusing on several strategic initiatives to drive future growth:
- Expanding the biosimilar portfolio.
- Increasing patient access globally.
- Capitalizing on emerging opportunities in the CRDMO sector.
Source: BSE
